Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus

ABSTRACT The filoviruses Marburg virus and Ebola virus cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (VSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Here, we performed a proof-of-concept study in order to determine the potential of having one single-injection vaccine capable of protecting nonhuman primates against Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), and Marburgvirus (MARV). In this study, 11 cynomolgus monkeys were vaccinated with a blended vaccine consisting of equal parts of the vaccine vectors VSVΔG/SEBOVGP, VSVΔG/ZEBOVGP, and VSVΔG/MARVGP. Four weeks later, three of these animals were challenged with MARV, three with CIEBOV, three with ZEBOV, and two with SEBOV. Three control animals were vaccinated with VSV vectors encoding a nonfilovirus GP and challenged with SEBOV, ZEBOV, and MARV, respectively, and five unvaccinated control animals were challenged with CIEBOV. Importantly, none of the macaques vaccinated with the blended vaccine succumbed to a filovirus challenge. As expected, an experimental control animal vaccinated with VSVΔG/ZEBOVGP and challenged with SEBOV succumbed, as did the positive controls challenged with SEBOV, ZEBOV, and MARV, respectively. All five control animals challenged with CIEBOV became severely ill, and three of the animals succumbed on days 12, 12, and 14, respectively. The two animals that survived CIEBOV infection were protected from subsequent challenge with either SEBOV or ZEBOV, suggesting that immunity to CIEBOV may be protective against other species of Ebola virus. In conclusion, we developed an immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species.

[1]  P Brès,et al.  [The epidemic of Ebola haemorrhagic fever in Sudan and Zaire, 1976: introductory note]. , 1978, Bulletin of the World Health Organization.

[2]  D. Cyranoski Ebola outbreak has experts rooting for answers , 2009, Nature.

[3]  B. Murphy,et al.  Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus , 2007, Journal of Virology.

[4]  Jon Cohen Did Merck's Failed HIV Vaccine Cause Harm? , 2007, Science.

[5]  B. Ramsey,et al.  Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. , 1998, Pediatrics.

[6]  Division on Earth Guide for the Care and Use of Laboratory Animals , 1996 .

[7]  R. Koup,et al.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates , 2003, Nature.

[8]  D. Dichek,et al.  Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. , 1997, The Journal of clinical investigation.

[9]  D. Normile Scientists Puzzle Over Ebola-Reston Virus in Pigs , 2009, Science.

[10]  R. Chanock,et al.  Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. , 1969, American journal of epidemiology.

[11]  B. Mothé,et al.  Development of a New Vaccine for the Prevention of Lassa Fever , 2005, PLoS medicine.

[12]  L. Fernando,et al.  Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment , 2006, The Lancet.

[13]  A. Sanchez,et al.  Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.

[14]  R. Koup,et al.  Competing Interests: GJN: , 2022 .

[15]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[16]  P. Formenty,et al.  Marburg Virus Angola Infection of Rhesus Macaques: Pathogenesis and Treatment with Recombinant Nematode Anticoagulant Protein c2 , 2007, The Journal of infectious diseases.

[17]  C. Boesch,et al.  Isolation and partial characterisation of a new strain of Ebola virus , 1995, The Lancet.

[18]  K. Johnson,et al.  MARBURG-VIRUS DISEASE IN KENYA , 1982, The Lancet.

[19]  H. Feldmann,et al.  Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine , 2006, Journal of Virology.

[20]  H. Feldmann,et al.  Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses , 2004, Journal of Virology.

[21]  Steven J M Jones,et al.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. , 2008, Vaccine.

[22]  W. Ian Lipkin,et al.  Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda , 2008, PLoS pathogens.

[23]  J. Maniloff,et al.  Virus taxonomy : eighth report of the International Committee on Taxonomy of Viruses , 2005 .

[24]  Steven J M Jones,et al.  Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates , 2008, PLoS pathogens.

[25]  S. Hazar,et al.  Filoviridae: Marburg and Ebola viruses. , 2000 .

[26]  W. Kalina,et al.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. , 2007, The Journal of infectious diseases.

[27]  D. Swenson,et al.  Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections , 2008, Clinical and Vaccine Immunology.

[28]  L. Fernando,et al.  Effective Post-Exposure Treatment of Ebola Infection , 2007, PLoS pathogens.

[29]  D. Simpson,et al.  A comparative study of strains of ebola virus isolated from southern sudan and northern zaire in 1976 , 1980, Journal of medical virology.

[30]  J. A. Comer,et al.  Marburgvirus Genomics and Association with a Large Hemorrhagic Fever Outbreak in Angola , 2006, Journal of Virology.

[31]  R. Sékaly The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? , 2008, The Journal of experimental medicine.

[32]  H. Feldmann,et al.  Marburg and Ebola viruses. , 1996, Advances in virus research.

[33]  H. Feldmann,et al.  Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates , 2008, Journal of Virology.

[34]  J. Smith,et al.  Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. , 1998, Virology.

[35]  P. Jahrling,et al.  Filovirus Pathogenesis in Nonhuman Primates , 2002 .

[36]  P. Jahrling,et al.  Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. , 1999, The Journal of infectious diseases.